Capricor Therapeutics, Inc.
CAPR$1.28B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO160 employees
Drugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
CAPR News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
CAP-1002
Cardiosphere-Derived Cells
Duchenne Muscular Dystrophy
OrphanFast Track
Deramiocel (CAP-1002)
Duchenne Muscular Dystrophy
CAP-2003
COVID-19 Cardiac
Cenderitide
Heart Failure
Allogeneic Cardiosphere-Derived Cells (CAP-1002)
Duchenne Muscular Dystrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CAP-1002 Cardiosphere-Derived Cells | Phase 3 | Duchenne Muscular Dystrophy | OrphanFast Track | - |
Deramiocel (CAP-1002) | Phase 3 | Duchenne Muscular Dystrophy | - | - |
CAP-2003 | Phase 2 | COVID-19 Cardiac | - | - |
Cenderitide | Phase 2 | Heart Failure | - | - |
Allogeneic Cardiosphere-Derived Cells (CAP-1002) | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply